Janghoon Choi

Title: Janghoon Choi: Innovator in Monoclonal Antibody Research

Introduction

Janghoon Choi is a prominent inventor based in Chungcheongbuk-do, South Korea. He is recognized for his significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies targeting the Middle East respiratory syndrome coronavirus (MERS-CoV). His innovative work has the potential to impact the diagnosis and treatment of this serious viral infection.

Latest Patents

Janghoon Choi holds a patent for a monoclonal antibody for the spike protein of the Middle East respiratory syndrome coronavirus. The patent details several monoclonal antibodies, including 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1, and 90-F2. These antibodies exhibit excellent attachment force to the full-length spike protein and the S1 domain of MERS-CoV. Notably, antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5, and 77-A6 demonstrate neutralizing capacity against MERS pseudovirus and MERS-CoV, making them valuable for therapeutic applications.

Career Highlights

Throughout his career, Janghoon Choi has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the Korea Center for Disease Control and Prevention. His experience in these institutions has equipped him with the knowledge and skills necessary to advance his research in infectious diseases.

Collaborations

Janghoon Choi has collaborated with notable colleagues, including Hansaem Lee and Sungsoon Kim. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the field of virology.

Conclusion

Janghoon Choi's work in monoclonal antibody research represents a significant advancement in the fight against MERS-CoV. His innovative contributions have the potential to improve diagnostic and therapeutic strategies for this viral infection.